Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
Upturn AI SWOT - About
Invesco Dynamic Pharmaceuticals ETF (PJP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/29/2025: PJP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type ETF | Historic Profit 7.63% | Avg. Invested days 62 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | ETF Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/29/2025 |
Key Highlights
Volume (30-day avg) - | Beta 0.45 | 52 Weeks Range 72.01 - 89.04 | Updated Date 06/29/2025 |
52 Weeks Range 72.01 - 89.04 | Updated Date 06/29/2025 |
Upturn AI SWOT
Invesco Dynamic Pharmaceuticals ETF
ETF Overview
Overview
The Invesco Dynamic Pharmaceuticals ETF (PJP) is designed to provide investment results corresponding to the price and yield of the Dynamic Pharmaceutical Intellidex Index. The fund invests in companies involved in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs.
Reputation and Reliability
Invesco is a well-established global investment management firm with a strong reputation. They offer a broad range of investment solutions and have a long track record.
Management Expertise
Invesco has a team of experienced portfolio managers and analysts with expertise in the pharmaceutical and healthcare sectors.
Investment Objective
Goal
The ETF aims to replicate the performance of the Dynamic Pharmaceutical Intellidex Index, focusing on capital appreciation.
Investment Approach and Strategy
Strategy: The ETF tracks an index composed of US pharmaceutical companies. The index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including: price momentum, earnings momentum, quality, management action, and value.
Composition The ETF primarily holds stocks of pharmaceutical companies. The ETF focuses on US equities and is rebalanced quarterly.
Market Position
Market Share: PJP holds a moderate market share within the pharmaceuticals ETF sector.
Total Net Assets (AUM): 41359229
Competitors
Key Competitors
- iShares U.S. Pharmaceuticals ETF (IHE)
- SPDR S&P Pharmaceuticals ETF (XPH)
Competitive Landscape
The pharmaceuticals ETF sector is moderately competitive. PJP's dynamic weighting methodology differentiates it but also results in higher turnover. IHE has a strong presence in market share and XPH is less concentrated which provides better risk diversification compared to PJP.
Financial Performance
Historical Performance: Historical financial performance data is not provided in this document but is available from financial data providers such as Bloomberg, Yahoo Finance, Google Finance, etc.
Benchmark Comparison: Benchmark comparison data is not provided in this document but is available from financial data providers such as Bloomberg, Yahoo Finance, Google Finance, etc.
Expense Ratio: 0.56
Liquidity
Average Trading Volume
PJP exhibits moderate liquidity with an average daily trading volume that can vary.
Bid-Ask Spread
PJP's bid-ask spread is typically around 0.1% but can widen during periods of market volatility.
Market Dynamics
Market Environment Factors
Economic indicators, healthcare policy changes, FDA approvals, drug pricing pressures, and overall market sentiment can affect the performance of PJP.
Growth Trajectory
Growth trends are correlated to the overall pharmaceutical sector's performance. Changes to the investment strategy, rebalancing of holdings, and the introduction of new index methodologies affect PJP's trajectory.
Moat and Competitive Advantages
Competitive Edge
PJP's primary advantage is its dynamic weighting methodology, which aims to identify and invest in companies with strong growth potential based on a proprietary model. This strategy seeks to outperform traditional market-cap weighted pharmaceutical ETFs. The ETF's focus on factors like price momentum, earnings momentum, quality, management action, and value aims to capture alpha. However, this can also lead to higher portfolio turnover and potentially higher transaction costs.
Risk Analysis
Volatility
PJP's volatility is moderate, and sensitive to events such as clinical trial results, regulatory changes, and shifts in market sentiment.
Market Risk
The ETF faces sector-specific risks, including patent expirations, drug pricing controversies, regulatory hurdles, and competition from generic drugs.
Investor Profile
Ideal Investor Profile
PJP is suitable for investors seeking targeted exposure to the pharmaceutical sector and comfortable with a more active investment approach.
Market Risk
PJP is suitable for investors with a moderate risk tolerance, seeking capital appreciation and sector-specific exposure to pharmaceuticals.
Summary
The Invesco Dynamic Pharmaceuticals ETF (PJP) offers exposure to the pharmaceutical sector through a dynamic weighting methodology. It targets capital appreciation by investing in companies based on factors like price momentum, earnings momentum, and value. While it presents the potential for outperformance, it also carries the risk of higher volatility and turnover compared to market-cap weighted ETFs. PJP is suitable for investors with a moderate risk tolerance and a desire for sector-specific exposure, but the dynamic weighting system could offer investors higher potential returns.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Invesco Official Website
- ETF.com
- Yahoo Finance
- Bloomberg
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Investment decisions should be based on your own research and risk tolerance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Invesco Dynamic Pharmaceuticals ETF
Exchange NYSE ARCA | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of common stocks of U.S. pharmaceutical companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.